RAPISCAN 400 micrograms, solution for injection bottle, 5 ml
Active ingredients: Regadenoson, Regadenoson hydrate
Commercialized according to BDPMDispensing in France: Prescription only, hospital use
Solution for injectionbottle, 5 mlintraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- RAPISCAN 400 microgrammes, solution injectable
- Pharmaceutical form
- solution injectable
- Route of administration
- intraveineuse
- Presentation description
- 1 flacon(s) de 5 ml
- Marketing authorisation holder
- GE HEALTHCARE (NORVEGE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 16 Mar 2015
- Prescription and dispensing conditions
- Prescription only, hospital use
- List I: prescription-only medicine
- Hospital use only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
69075222CIP75849639CIP133400958496394Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| RÉGADÉNOSONsolution | 0,08 mg · 1 ml de solution | FT |
| RÉGADÉNOSON MONOHYDRATÉsolution | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.